Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Hepatology (Baltimore, Md.)
|
April 8, 2015
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
David Wyles, Paul Pockros, Giuseppe Morelli, et al.
Advances in Therapy
|
August 6, 2020
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Pietro Lampertico, Stefan Mauss, Marcello Persico, et al.
Advances in Therapy
|
September 11, 2020
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Pietro Lampertico, Stefan Mauss, Marcello Persico, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
November 21, 2017
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir
Zobair M Younossi, Maria Stepanova, Stuart Gordon, et al.
Viruses
|
October 28, 2023
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
Steven Flamm, Eric Lawitz, Brian Borg, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 18, 2018
Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection
Steven Flamm, K Rajender Reddy, Neddie Zadeikis, et al.
Hepatology (Baltimore, Md.)
|
September 27, 2007
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial
Ira M Jacobson, Robert S Brown, Bradley Freilich, et al.
Cardiovascular and Interventional Radiology
|
April 7, 2021
Comparing Real World, Personalized, Multidisciplinary Tumor Board Recommendations with BCLC Algorithm: 321-Patient Analysis
Monica M Matsumoto, Samdeep Mouli, Priyali Saxena, et al.
Hepatology (Baltimore, Md.)
|
June 22, 2010
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection
Andrew J Muir, Mitchell L Shiffman, Atif Zaman, et al.
Journal of Hepatology
|
November 9, 2010
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program
Thierry Poynard, Mona Munteanu, Massimo Colombo, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Hepatology (Baltimore, Md.)
|
April 8, 2015
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
David Wyles, Paul Pockros, Giuseppe Morelli, et al.
Advances in Therapy
|
August 6, 2020
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Pietro Lampertico, Stefan Mauss, Marcello Persico, et al.
Advances in Therapy
|
September 11, 2020
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Pietro Lampertico, Stefan Mauss, Marcello Persico, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
November 21, 2017
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir
Zobair M Younossi, Maria Stepanova, Stuart Gordon, et al.
Viruses
|
October 28, 2023
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
Steven Flamm, Eric Lawitz, Brian Borg, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 18, 2018
Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection
Steven Flamm, K Rajender Reddy, Neddie Zadeikis, et al.
Hepatology (Baltimore, Md.)
|
September 27, 2007
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial
Ira M Jacobson, Robert S Brown, Bradley Freilich, et al.
Cardiovascular and Interventional Radiology
|
April 7, 2021
Comparing Real World, Personalized, Multidisciplinary Tumor Board Recommendations with BCLC Algorithm: 321-Patient Analysis
Monica M Matsumoto, Samdeep Mouli, Priyali Saxena, et al.
Hepatology (Baltimore, Md.)
|
June 22, 2010
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection
Andrew J Muir, Mitchell L Shiffman, Atif Zaman, et al.
Journal of Hepatology
|
November 9, 2010
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program
Thierry Poynard, Mona Munteanu, Massimo Colombo, et al.
Page
of 3